AKEEGA^®—the only FDA-approved treatment option combining two drugs into one tablet for adults with BRCA+ metastatic castration-resistant prostate cancer (mCRPC)

Stay up-to-date about AKEEGA^®

Janssen Biotech, Inc., our affiliates, and our service providers will use the information you provide to send you information about AKEEGA^® or BRCA+ mCRPC and for any optional requests you may select. Please note that the subject line of emails you receive may include the AKEEGA^® name. You may unsubscribe by following the instructions near the end of each message. Our Privacy Policy further governs the use of the information you provide.

*Required field

First Name*

Last Name*

Email Address*

ZIP Code

Please select what best describes you*

Select one

Yes, I would like to receive information and updates about other Johnson & Johnson products and services.

*By providing consent, you agree to the collection and use of your Sensitive Personal Information (SPI). Examples of SPI may include, but are not limited to, health-related information. We use this information consistent with our Privacy Policy, including to personalize the information you receive, fulfill any requests you submit, and to research, develop, and improve our products and services. By checking the box, you indicate that you read, understand, and agree to such collection and use of your SPI.

Leave this field blank

Submit